Shanghai Fudan Forward S&T Co Ltd
SSE:600624
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shanghai Fudan Forward S&T Co Ltd
SSE:600624
|
CN |
Multiples-Based Value
The Multiples-Based Value for Shanghai Fudan Forward S&T Co Ltd (600624) under the Base Case is 4.68 CNY. Compared with the current market price of 4.65 CNY, the stock appears Undervalued by 1%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
Competitors Multiples
Shanghai Fudan Forward S&T Co Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
S
|
Shanghai Fudan Forward S&T Co Ltd
SSE:600624
|
3.2B CNY | 4.8 | -26.5 | -33.2 | -33.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
900.7B USD | 13.8 | 43.6 | 29.4 | 31.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
581B USD | 6.2 | 21.7 | 15.1 | 18.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236B GBP | 5.3 | 30.3 | 16.8 | 23.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.4 | 11.5 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
304.8B USD | 4.7 | 16.7 | 10.3 | 12.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
232.5B CHF | 5.2 | 20.8 | 12.8 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.2B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.2B USD | 2.5 | 16.9 | 7.1 | 8.8 |